远大医药(00512)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

00512 远大医药

未开盘 11-11 16:08:05

4.370

-0.060

-1.35%

最高4.440	最低4.345	成交量168.60万
今开4.430	昨收4.430	日振幅2.14%
总市值155.14亿	流通市值155.12亿	总股本35.50亿
成交额737.85万	换手率0.05%	流通股本35.50亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"00512","market":"HK","secType":"STK","nameCN":"远大医药","latestPrice":4.37,"timestamp":1794384485002,"preClose":4.43,"halted":0,"volume":1686000,"delay":0,"changeRate":-0.013544018058690658,"floatShares":3549571148,"shares":3550000000,"eps":0.3544,"marketStatus":"未开盘","change":-0.06,"latestTime":"11-11 16:08:05","open":4.43,"high":4.44,"low":4.345,"amount":7378484,"amplitude":0.021445,"askPrice":4.37,"askSize":5500,"bidPrice":4.36,"bidSize":5000,"shortable":3,"etf":0,"ttmEps":0.316754,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1794447000000},"marketStatusCode":0,"adr":0,"listingDate":819302400000,"exchange":"SEHK","adjPreClose":4.43,"dividendRate":0.038673,"openAndCloseTimeList":[[1794360600000,1794369600000],[1794373200000,1794384000000]],"volumeRatio":0.48153914304057627,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/00512","defaultTab":"news","newsList":[{"id":"2682360684","title":"破局慢病赛道：远大医药（00512）创新中成药国内临床首例患者入组 或填补偏头痛预防性治疗空白","url":"https://stock-news.laohu8.com/highlight/detail?id=2682360684","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682360684?lang=zh_cn&edition=full","pubTime":"2026-11-10 17:08","pubTimestamp":1794301706,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，近日，远大医药用于预防性治疗偏头痛的1.1类中药创新药GPN01020国内II期临床研究完成了首例患者入组。而GPN01020所对应的偏头痛预防性治疗场景，恰恰是当前临床需求尚未被充分满足的领域。其中，用于治疗抑郁症的中药创新药GPN01360系国家“重大新药创制”专项重点支持研发的中药创新成果，其在中国开展的III期临床研究已于2026年7月完成首例患者入组给药。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1521101.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"破局慢病赛道：远大医药（00512）创新中成药国内临床首例患者入组 或填补偏头痛预防性治疗空白","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","00512"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105272152","title":"远大医药（00512）创新中药GPN01020在华II期临床完成首例患者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=1105272152","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1105272152?lang=zh_cn&edition=full","pubTime":"2026-11-10 17:05","pubTimestamp":1794301559,"startTime":"0","endTime":"0","summary":"11月10日，远大医药公告称，用于偏头痛预防性治疗的1.1类中药创新药GPN01020在中国开展的II期临床研究已完成首例患者入组。该研究为随机、双盲、安慰剂平行对照的多中心试验，计划共纳入180例偏头痛患者，评估GPN01020在预防偏头痛发作的有效性、安全性及耐受性。GPN01020由三级甲等医院院内制剂转化而来，已在该院临床应用逾二十年。公司重申，GPN01020仍处于研发阶段，未来能否获批上市及商业化存在不确定性。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00512"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682360822","title":"远大医药(00512.HK)用于预防性治疗偏头痛的中药创新药 GPN01020 在中国开展的 II 期临床研究完成首例患者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2682360822","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682360822?lang=zh_cn&edition=full","pubTime":"2026-11-10 17:04","pubTimestamp":1794301464,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1191","06978","00512","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119104270","title":"远大医药（00512）11月25日召开股东特别大会　拟即时更换核数师","url":"https://stock-news.laohu8.com/highlight/detail?id=1119104270","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1119104270?lang=zh_cn&edition=full","pubTime":"2026-11-05 17:15","pubTimestamp":1793870133,"startTime":"0","endTime":"0","summary":"远大医药今日发布股东特别大会通知。大会将于2026年11月25日（星期三）11:00在香港皇后大道中99号中环中心3302室举行，股东名册将在11月20日至25日期间暂停过户登记。\\n\\n股东可委任一名或多名代表出席投票，委任表格及相关授权文件须于大会召开48小时前送达香港中央证券登记有限公司。公司提醒股东关注八号或以上台风信号、黑色暴雨警告等恶劣天气情况下的延期安排，届时将另行公告。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00512"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681301552","title":"港股异动 | 远大医药(00512)涨近5% CBT-001国际多中心III期研究达主要临床终点 显著控制翼状胬肉病灶","url":"https://stock-news.laohu8.com/highlight/detail?id=2681301552","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681301552?lang=zh_cn&edition=full","pubTime":"2026-11-05 10:35","pubTimestamp":1793846112,"startTime":"0","endTime":"0","summary":"消息面上，11月5日，远大医药发布公告，公司全球创新眼科药物CBT-001国际多中心III期临床试验达到主要临床终点，CBT-001被证实能够改变翼状胬肉疾病进程。这意味着，CBT-001是全球首款通过在统计学上显著改善充血及病变大小，展现出对翼状胬肉治疗作用的药物，其未来有望填补翼状胬肉治疗空白，为全球患者带来全新的选择。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1518834.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","BK4588","BK1191","VXUS","KCAI","00512"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681920060","title":"远大医药(00512.HK)：全球创新眼科药物CBT-001用于翼状胬肉的国际多中心III期临床试验达到主要临床终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2681920060","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681920060?lang=zh_cn&edition=full","pubTime":"2026-11-05 08:21","pubTimestamp":1793838071,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1191","00512"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142564920","title":"远大医药（00512）披露：创新眼科药物CBT-001治疗翼状胬肉国际Ⅲ期试验达主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=1142564920","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1142564920?lang=zh_cn&edition=full","pubTime":"2026-11-05 08:15","pubTimestamp":1793837744,"startTime":"0","endTime":"0","summary":"2026年11月5日，远大医药集团有限公司公告称，其用于治疗翼状胬肉的全球创新眼科药物CBT-001在国际多中心随机、双盲、安慰剂对照Ⅲ期临床研究[CS-301]中达到两项主要临床终点。试验共入组659名翼状胬肉患者，分别接受0.1%或0.2%浓度CBT-001眼用乳液或安慰剂，每日两次给药，治疗期24个月。患者招募自2022年6月起在美国、中国、纽西兰、澳大利亚及印度开展。公司提醒投资者，CBT-001目前仍处于研发阶段，上市审批及商业化存在不确定性，投资者需审慎决策。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00512"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134600361","title":"远大医药更新2026年10月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1134600361","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1134600361?lang=zh_cn&edition=full","pubTime":"2026-11-03 20:22","pubTimestamp":1793708556,"startTime":"0","endTime":"0","summary":"远大医药集团有限公司于2026年11月3日披露2026年10月股份变动月报表，报告期为2026年10月。公告显示，公司本月未发生新增发行、回购或注销活动，股本自上月保持不变。与上月底相比，本月股本结构未发生实际变动，公司确认已经符合适用的最低公众持股量要求。本次月报由公司秘书傅天忠签署。根据上述公告，远大医药截至2026年10月31日的股本维持稳定，未发生任何发行或回购变动。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00512"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148792794","title":"远大医药(00512)发布补充公告　拟终止国卫聘任并改聘德勤为新核数师","url":"https://stock-news.laohu8.com/highlight/detail?id=1148792794","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1148792794?lang=zh_cn&edition=full","pubTime":"2026-11-03 20:15","pubTimestamp":1793708133,"startTime":"0","endTime":"0","summary":"远大医药集团有限公司11月3日刊发补充公告称，公司董事会已决议建议终止国卫作为公司核数师的任命，并拟委任德勤为截至2026年12月31日止年度的新任核数师，相关决议尚待股东于股东特别大会审议并批准。2026年3月26日，审核委员会审阅并批准公布2025年年度业绩初步公告；2026年8月25日，公司与德勤签署服务协议，开展财务健康检查；2026年8月至9月，德勤进行财务健康检查；2026年9月，管理层口头邀请德勤就2026年度审计提交建议书及报价；","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00512"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187016364","title":"远大医药（00512）拟于股东特别大会更换核数师 德勤候任收取约港币4.38百万元审计费","url":"https://stock-news.laohu8.com/highlight/detail?id=1187016364","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1187016364?lang=zh_cn&edition=full","pubTime":"2026-10-22 21:20","pubTimestamp":1792675241,"startTime":"0","endTime":"0","summary":"远大医药10月22日公告称，为配合集团海外扩张战略，董事会建议更换外部核数师，提议终止国卫会计师事务所有限公司担任截至2026年12月31日止年度核数师的委任，并委任德勤关黄陈方会计师行为新任核数师，任期至公司下一届股东周年大会结束。该议案将提交即将召开的股东特别大会表决。股东特别大会将于短期内召开，决议案包括终止国卫及委任德勤两项内容。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00512"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677966336","title":"远大医药(00512)建议委任德勤为新任核数师","url":"https://stock-news.laohu8.com/highlight/detail?id=2677966336","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677966336?lang=zh_cn&edition=full","pubTime":"2026-10-22 21:18","pubTimestamp":1792675090,"startTime":"0","endTime":"0","summary":"智通财经APP讯，远大医药(00512)发布公告，为支持本集团的海外扩张策略，董事会认为现时是轮换本公司外部核数师的适当时机。本公司根据董事会审核委员会的建议，拟终止本公司现任核数师国卫会计师事务所有限公司(国卫)作为本公司截至2026年12月31日止年度的核数师的委任(建议终止)，并委任德勤 • 关黄陈方会计师行(德勤)为本公司截至2026年12月31日止年度之新任核数师，以填补因“建议终止”所产生之临时空缺，并任职至本公司下届股东周年大会结束为止(建议委任，连同“建议终止”，统称“建议更换核数师”)。建议更换核数师须待(其中包括)本公司将召开之股东特别大会通过相关决议案后，方可作实。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1511107.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","00512"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676296658","title":"远大医药满沐安中国首批处方正式落地","url":"https://stock-news.laohu8.com/highlight/detail?id=2676296658","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676296658?lang=zh_cn&edition=full","pubTime":"2026-10-20 09:56","pubTimestamp":1792461403,"startTime":"0","endTime":"0","summary":"近日，远大医药（0512.HK）用于治疗蠕形螨睑缘炎的创新眼科药物满沐安?[TP-03，GPN01768（洛替拉纳滴眼液）0.25%]在北京、上海、广东、天津、重庆、浙江、福建、湖北及陕西等地的11家医疗机构开出了首批处方，标志着大中华区首款获批用于治疗蠕形螨睑缘炎的药物已进入临床实践，正式终结国内蠕形螨睑缘炎患者“无药可用”困境。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202610203900982119.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202610203900982119.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1191","00512"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676637965","title":"20亿美元重磅产品正式落地！远大医药（00512）满沐安®终结国内蠕形螨睑缘炎患者“无药可用”困境","url":"https://stock-news.laohu8.com/highlight/detail?id=2676637965","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676637965?lang=zh_cn&edition=full","pubTime":"2026-10-20 08:12","pubTimestamp":1792455170,"startTime":"0","endTime":"0","summary":"近日，远大医药（00512）用于治疗蠕形螨睑缘炎的创新眼科药物满沐安®[TP-03，GPN01768（洛替拉纳滴眼液）0.25%]在北京、上海、广东、天津、重庆、浙江、福建、湖北及陕西等地的11家医疗机构开出了首批处方。","market":"fut","thumbnail":"https://img.zhitongcaijing.com/image/20261020/20261020081301_98811.png?x-oss-process=image/format,jpg/quality,q_60","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20261020/20261020081301_98811.png?x-oss-process=image/format,jpg/quality,q_60"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1509122.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1191","00512"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165634895","title":"远大医药更新9月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1165634895","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1165634895?lang=zh_cn&edition=full","pubTime":"2026-10-05 16:43","pubTimestamp":1791189781,"startTime":"0","endTime":"0","summary":"远大医药于2026年10月5日向香港联合交易所有限公司递交的最新月报表显示，公司截至2026年9月30日止月度内未发生新的股份发行、购回或注销等变动，股本结构保持稳定。与上月相比，报告期末注册股本数量未发生增减。公告指出，该公司已确认符合香港联交所相关上市规则要求的最低公众持股量门槛。公告表示，远大医药已严格遵循香港联交所《上市规则》及其他相关法律法规规范运作。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00512"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159778352","title":"远大医药2026年上半年营收63.89亿元，经调整净利润10.41亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1159778352","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1159778352?lang=zh_cn&edition=full","pubTime":"2026-09-24 17:25","pubTimestamp":1790241924,"startTime":"0","endTime":"0","summary":"2026年上半年，远大医药实现营收约63.89亿港元，同比增长3.2%。经调整净利润约10.41亿港元，较上年同期的9.73亿港元增长约7.1%，经调整净利润率约16.3%。同期毛利约33.68亿港元，同比下降约7.8%。经营活动所得现金净额约1.42亿港元，较上年同期增长约91.3%。研发投入约7.6亿港元，占总营收比约11.9%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"远大医药2026年上半年营收63.89亿元，经调整净利润10.41亿元","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00512"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666307419","title":"【券商聚焦】国信证券维持远大医药（00512）优于大市评级 指核药板块高速放量","url":"https://stock-news.laohu8.com/highlight/detail?id=2666307419","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666307419?lang=zh_cn&edition=full","pubTime":"2026-09-09 14:00","pubTimestamp":1788933625,"startTime":"0","endTime":"0","summary":"金吾财讯 | 国信证券发布研报指，远大医药 2026年上半年实现收入63.89亿港元，同比增长3.2%；归母净利润10.62亿港元，扣除对Telix投资的公允价值变动和处置收益后，经调整经营性纯利9.73亿港元，同比下降6.6%。远大医药自2015年以来加速创新转型，已在核药抗肿瘤、心脑血管精准介入以及制药科技三个板块分别构建了“梯度化+差异化”的管线，期待核药板块的临床进展和商业化放量，维持“优于大市”评级。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250109/YmQzNzBkZGZmOTg1MzM5MTQzMTA0Ng==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/YmQzNzBkZGZmOTg1MzM5MTQzMTA0Ng==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1991174","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KCE","00512","002736"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665319142","title":"执行董事周超增持远大医药(00512)2.15万股 每股作价4.88港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2665319142","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665319142?lang=zh_cn&edition=full","pubTime":"2026-09-07 19:25","pubTimestamp":1788780313,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新数据显示，9月7日，执行董事周超增持远大医药(00512)2.15万股，每股作价4.88港元，总金额约为10.49万港元。增持后最新持股数目为53.25万股，最新持股比例为0.02%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1492964.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","00512","EWH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665319128","title":"执行董事周超增持远大医药(00512.HK)2.15万股 每股作价4.88港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2665319128","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665319128?lang=zh_cn&edition=full","pubTime":"2026-09-07 19:25","pubTimestamp":1788780313,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1191","00512"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120588679","title":"远大医药：周超增持，好仓比例升至0.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=1120588679","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1120588679?lang=zh_cn&edition=full","pubTime":"2026-09-07 17:22","pubTimestamp":1788772955,"startTime":"0","endTime":"0","summary":"周超于2026年9月7日以每股均价4.88港元买入远大医药股份2.15万股，涉资约10.49万港元。周超此次增持前持有远大医药好仓51.10万股，占比0.01%；增持后持股量为53.25万股，好仓比例升至0.02%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00512"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137380893","title":"远大医药更新2026年8月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1137380893","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1137380893?lang=zh_cn&edition=full","pubTime":"2026-09-02 16:41","pubTimestamp":1788338478,"startTime":"0","endTime":"0","summary":"远大医药2026年9月2日发布了截至2026年8月31日止的证券变动月报表。公告显示，公司报告期内注册股本维持不变，未发生新增发行、股份购回或注销等活动。已发行普通股数量为3,549,571,148股，库藏股份数量为0股，与上月底持平，股本总数保持稳定。公告还显示，公司目前公众持股量已符合香港联交所规定的最低公众持股量要求。本次公告由公司秘书傅天忠签署。远大医药将继续关注市场动态，严格遵守合规要求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00512"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.chinagrandpharm.com","stockEarnings":[{"period":"1week","weight":0.0198},{"period":"1month","weight":-0.0562},{"period":"3month","weight":-0.1793},{"period":"6month","weight":-0.2363},{"period":"1year","weight":-0.4675},{"period":"ytd","weight":-0.424}],"compareEarnings":[{"period":"1week","weight":0.0166},{"period":"1month","weight":0.0018},{"period":"3month","weight":-0.0425},{"period":"6month","weight":-0.0634},{"period":"1year","weight":-0.0892},{"period":"ytd","weight":-0.0513}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"远大医药集团有限公司是一家主要从事医药业务的投资控股公司。该公司主要从事制造及销售医药制剂及医疗器械。该公司还从事制造及销售生物技术产品、健康产品、精品原料药和其他产品。该公司的主要产品包括核药抗肿瘤诊疗及心脑血管介入诊疗科技产品。","yearOnYearQuotes":[{"month":1,"riseRate":0.451613,"avgChangeRate":0.084145},{"month":2,"riseRate":0.709677,"avgChangeRate":0.104891},{"month":3,"riseRate":0.387097,"avgChangeRate":0.015748},{"month":4,"riseRate":0.612903,"avgChangeRate":0.013455},{"month":5,"riseRate":0.451613,"avgChangeRate":0.076266},{"month":6,"riseRate":0.354839,"avgChangeRate":-0.048729},{"month":7,"riseRate":0.387097,"avgChangeRate":-0.011524},{"month":8,"riseRate":0.387097,"avgChangeRate":0.005503},{"month":9,"riseRate":0.451613,"avgChangeRate":-0.038601},{"month":10,"riseRate":0.483871,"avgChangeRate":-0.018224},{"month":11,"riseRate":0.516129,"avgChangeRate":0.082777},{"month":12,"riseRate":0.5,"avgChangeRate":-0.007406}],"exchange":"SEHK","name":"远大医药","nameEN":"GRAND PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"远大医药(00512)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供远大医药(00512)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"远大医药,00512,远大医药股票,远大医药股票老虎,远大医药股票老虎国际,远大医药行情,远大医药股票行情,远大医药股价,远大医药股市,远大医药股票价格,远大医药股票交易,远大医药股票购买,远大医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"远大医药(00512)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供远大医药(00512)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}